Significant advancements and fifteen month extension for the RBDCOV project


The European Commission has granted a 15-month extension to the RBDCOV project, allowing researchers additional time to recruit volunteers for the HH-3 clinical trial. This trial assesses the efficacy, tolerability, and safety of the BIMERVAX® COVID-19 vaccine as a booster shot in adolescents aged 12 to 17.

The project, led by Vall d’Hebron University Hospital, has seen encouraging progress with over 240 volunteers already enrolled. To achieve the target of 300 participants,

Read More